Recombinant measles AIK-C vaccine strain expressing the prM-E antigen of Japanese encephalitis virus

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Higuchi, Akira ^a   Toriniwa, Hiroko ^a   Komiya, Tomoyoshi ^a   Nakayama, Tetsuo ^b  

^a DAIICHI SANKYO CO   (Japan)

^b KITASATO INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; COMPLEMENTARY DNA; E PROTEIN; EIA ANTIBODY; NEUTRALIZING ANTIBODY; PA ANTIBODY; PRM PROTEIN; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS PROTEIN; JAPANESE ENCEPHALITIS VACCINE; MEASLES VACCINE; RECOMBINANT VACCINE;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; COTTON RAT; E GENE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; JAPANESE ENCEPHALITIS VIRUS; MEASLES AIK C VACCINE STRAIN; MEASLES VIRUS; MOLECULAR CLONING; NONHUMAN; PRM GENE; PROTEIN EXPRESSION; VIROGENESIS; VIRUS GENE; VIRUS RECOMBINANT; ANIMAL; CHLOROCEBUS AETHIOPS; ENCEPHALITIS, JAPANESE; FEMALE; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; MEASLES; RAT; VERO CELL LINE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; ENCEPHALITIS VIRUS, JAPANESE; ENCEPHALITIS, JAPANESE; FEMALE; HEK293 CELLS; HUMANS; JAPANESE ENCEPHALITIS VACCINES; MEASLES; MEASLES VACCINE; MEASLES VIRUS; RATS; VACCINES, SYNTHETIC; VERO CELLS;

EID: 84960886482     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0150213     Document Type: Article

References (34)

1. WHO (2015) Japanese encephalitis vaccines: WHO position paper-February 2015. Wkly Epidemiol Rec 90: 69-88. PMID: 25726573
2. Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, et al. (2011) Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ l 89: 766-774.
3. Halstead S, Jacobson J, Dubischar-Kastner K (2013) Japanese encephalitis vaccines. In Plotkin S, Orenstein W, Offit P, editors. Vaccines 6 th edition, Saunders Elesvier pp312-351.
4. Konishi E, Shida M, Yamamoto S, Arai S, Tanaka-Taya K, Okabe N (2006) Natural infection with Japanese encephalitis virus among inhabitants of Japan: a nationwide survey of antibodies against nonstructural 1 protein. Vaccine 24: 3054-3056. PMID: 16460843
5. WHO Meeting report (2007) WHO informal consultation on the scientific basis for production of inactivated Japanese encephalitis vaccines for human use, Geneva, Switzerland, 1-2 June 2006. Vaccine 25: 5233-5243. PMID: 17590244
6. Sugawara K, Nishiyama K, Ishikawa Y, Abe M, Sonoda K, Komatsu K, et al. (2002) Development of Vero cell-derived inactivated Japanese encephalitis vaccine. Biologicals 30: 303-314. PMID: 12421588
7. Miyazaki C, Okada K, Ozaki T, Hirose M, Iribe K, Yokote H, et al. (2014) Phase III clinical trials comparing the immunogenicity and safety of Vero cell-derived Japanese encephalitis vaccine ENCEVAC(R) with those of mouse brain-derived vaccine using the Beijing-1 strain. Clin Vaccine Immunol 21: 188-95. doi: 10.1128/CVI.00377-13 PMID: 24334689
8. Tauber E, Kollaritsch H, Korinek M, Rendi-Wagner P, Jilma B, Firbas C, et al. (2007) Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomized controlled trial. Lancet 370: 1847-1853. PMID: 18061060
9. Ni H, Chang GJ, Xie H, Trent DW, Barrett AD (1995) Molecular basis of attenuation of neurovirulence of wild-type Japanese encephalitis virus strain SA14. J Gen Virol 76; 409-413. PMID: 7844560
10. Chambers TJ, Nestorowicz A, Mason PW, Rice CM (1999) Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J Virol 73: 3095-3101. PMID: 10074160
11. Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J (2010) Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 28, 632-649. doi: 10.1016/j.vaccine.2009.09.098 PMID: 19808029
12. Appaiahgari MB, Vrati S, (2010) IMOJEV1: a Yellow fever virus-based novel Japanese encephalitis vaccine. Expert Rev Vaccines 9:1371-1384. doi: 10.1586/erv.10.139 PMID: 21105774
13. Sawada A, Komase K, Nakayama T. (2011) AIK-C measles vaccine expressing fusion protein respiratory syncytial virus induces protective antibodies in cotton rats. Vaccine 29: 1481-1490. doi: 10.1016/j. vaccine.2010.12.028 PMID: 21185852
14. Yamaji Y, Nakayama T (2014) Recombinant measles viruses expressing respiratory syncytial virus proteins induced virus-specific CTL responses in cotton rats. Vaccine 32: 4529-4536. doi: 10.1016/j. vaccine.2014.06.024 PMID: 24951869
15. Kimura-Kuroda J, Yasui K (1988) Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. J Immunol 141: 3606-3610. PMID: 2460542
16. Konishi E, Yamaoka M, Khin SW, Kurane I, Takada K, Mason PW (1999) The anamnestic neutralizing antibody response is critical for protection of mice from challenge following vaccination with a plasmid encoding the Japanese encephalitis virus premembrane and envelope genes. J Virol 73: 5527-5534. PMID: 10364301
17. Pan CH, Chen HW, Huang HW, Tao MH (2001) Protective mechanisms induced by a Japanese encephalitis virus DNA vaccine: requirement for antibody but not CD8(+) cytotoxic T-cell responses. J Virol 75: 11457-11463. PMID: 11689627
18. Hashimoto T, Nomoto A, Watanabe K, Mori T, Takezawa T, Aizawa C, et al. (1988) Molecular cloning and complete nucleotide sequence of the genome of Japanese encephalitis virus Beijing-1 strain. Virus Genes 1: 305-317. PMID: 3245133
19. Toriniwa H, Komiya T (2008) Long-term stability of Vero cell-derived inactivated Japanese encephalitis vaccine prepared using serum-free medium. Vaccine 26: 3680-3689. doi: 10.1016/j.vaccine.2008.04. 076 PMID: 18534722
20. Lee T, Komiya T, Watanabe K, Aizawa C, Hashimoto H (1995) Immune response in mice infected with the attenuated Japanese encephalitis vaccine strain SA14-14-2. Arch Virol 39: 161-164.
21. Komase K, Nakayama T, Iijima M, Miki K, Kawanishi R, Uejima H (2006) The phosphoprotein of attenuated measles AIK-C vaccine strain contributes to its temperature-sensitive phenotype. Vaccine 24: 826-834. PMID: 16140429
22. Xu X-G, Wang Z-S, Zhang Q, Li Z-C, Zhao H-N, Li W, et al. (2011) Baculovirus surface display of E envelope glycoprotein of Japanese encephalitis virus and its immunogenicity of the displayed proteins in mouse and swine models. Vaccine 29: 636-643. doi: 10.1016/j.vaccine.2010.11.045 PMID: 21115062
23. Konishi E1, Kitai Y, Nishimura K, Harada S (2012) Follow-Up Survey of Japanese Encephalitis Virus Infection in Kumamoto Prefecture, South-West Japan: Status during 2009-2011. Jpn J Infect Dis 65: 448-450. PMID: 22996224
24. Lobigs M, Pavy M, Hall RA, Lobigs P, Cooper P, Komiya T, et al. (2010) An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel neutralizing antibody against homologous and heterologous flaviviruses. J Gen Virol 91: 1407-1417. doi: 10.1099/vir.0.019190-0 PMID: 20130134
25. Sohn YM, Tandan JB, Yoksan S, Ji M, Ohrr H (2008) A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-12 Japanese encephalitis vaccine: immunogenicity and anamnestic responses. Vaccine 26: 1638-1643. doi: 10.1016/j.vaccine.2008.01.021 PMID: 18294743
26. Bray M, Lai CJ (1991) Construction of intertypic chimeric dengue viruses by substitution of structural protein genes. Proc. Natl. Acad. Sci. U. S. A. 88: 10342-10346. PMID: 1682924
27. Nam JH, Wyatt LS, Chae SL, Cho HW, Park YK, Moss B (1999) Protection against lethal Japanese encephalitis virus infection of mice by immunization with the highly attenuated MVA strain of vaccinia virus expressing JEV prM and E genes. Vaccine 17: 261-268. PMID: 9987162
28. Sasaki K (1974) Studies on the modification of the live AIK measles vaccine. I. Adaptation of the further attenuated AIK measles virus (the strain of AIK-L33) to chick embryo cells. Kitasato Arch Exp Med 47: 1-12.
29. Makino S (1983) Development and characteristics of live AIK-C measles virus vaccine: a brief report. Rev Infect Dis 5: 504-505. PMID: 6410489
30. Nakayama T, Komase K, Uzuka R, Hoshi A, Okafuji T. (2001) Leucine at position 278 of the AIK-C measles virus vaccine strain fusion protein is responsible for reduced syncytium formation. J Gen Virol 82: 2143-2150. PMID: 11514723
31. Tidjani O, Grunitsky B, Guérin N, Lévy-Bruhl D, Lecam N, Xuereff C, et al. (1989) Serological effects of Edmonston-Zagreb, Schwarz, and AIK-C measles vaccine strains given at ages 4-5 or 8-10 months. Lancet II (8676): 1357-1360.
32. Bolotovski VM, Grabowsky M, Clements CJ, Albrecht P, Brenner ER, Zargaryantzs AI, et al. (1994) Immunization of 6 and 9 month old infants with AIK-C, Edmonston-Zagreb, Leningrad-16 and Schwarz strains of measles vaccine. Int J Epidemiol 23: 1069-1077. PMID: 7860158
33. Nkrumah FK, Osei-Kwasi M, Dunyo SK, Koram KA, Afari EA (1998) Comparison of AIK-C measles vaccine in infants at 6 months with Schwarz vaccine at 9 months: a randomized controlled trial in Ghana. Bull WHO 76: 353-359. PMID: 9803586
34. Nakayama T (2013) Vaccine chronicle in Japan. J Infect Chemother 19: 787-798. doi: 10.1007/s10156-013-0641-6 PMID: 23835871